GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » Float Percentage Of Total Shares Outstanding

NRXP (NRX Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 88.91% (As of Mar. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NRX Pharmaceuticals's float shares is 15.04 Mil. NRX Pharmaceuticals's total shares outstanding is 16.92 Mil. NRX Pharmaceuticals's float percentage of total shares outstanding is 88.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NRX Pharmaceuticals's Insider Ownership is 5.14%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NRX Pharmaceuticals's Institutional Ownership is 8.67%.


NRX Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

NRX Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=15.04/16.92
=88.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NRX Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Executives
Jonathan C Javitt director, 10 percent owner, officer: Chief Scientist 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz director C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard director, officer: Chief Executive Officer 1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt 10 percent owner 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg officer: Chief Financial Officer C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof officer: Chief Comm. & Patient Officer 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault officer: General Counsel & Secretary 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster director C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
William Fricker officer: CFO & Treasurer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Big Rock Partners Sponsor, Llc 10 percent owner 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Richard Ackerman director, 10 percent owner, officer: President & CEO 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483

NRX Pharmaceuticals Headlines

From GuruFocus

Q2 2024 NRX Pharmaceuticals Inc Earnings Call Transcript

By GuruFocus Research 08-15-2024